Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Mogamulizumab induces cytotoxicity against CCR4+ lymphoma cells by antibody-dependent cell-mediated cytotoxicity in advanced cutaneous T-cell lymphoma patients. Since the efficacy of mogamulizumab in mycosis fungoides (28.6%) is lower than that in Sézary syndrome (47.1%), reagents that enhance the antitumor immune response induced by mogamulizumab are needed to further optimize its use for the treatment of erythrodermic mycosis fungoides. In this report, we present a case of erythrodermic mycosis fungoides successfully treated with mogamulizumab followed by etoposide monotherapy.

Original languageEnglish
Pages (from-to)29-32
Number of pages4
JournalCase Reports in Oncology
Volume11
Issue number1
DOIs
Publication statusPublished - 2018 Jan 19

Keywords

  • Erythrodermic mycosis fungoides
  • Etoposide
  • Mogamulizumab

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Successful Treatment of Erythrodermic Mycosis Fungoides with Mogamulizumab Followed by Etoposide Monotherapy'. Together they form a unique fingerprint.

  • Cite this